Georgia Institute of Technology
Institutional Biosafety Committee
Meeting Minutes
October 2, 2025
10:00 AM

Voting Members Present:
K-BIOL (Interim Chair)
D-NAM
K-NAM
T-ORIA
M-ORIA
S-BME
K-EHS

Voting Members Absent:
A-ME (Chair)
S-BIOL

Non-voting Attendees:
KS-ORIA
KA-ORIA
P-ORIA

The full Committee roster is posted publicly on the Georgia Tech website. All requests from the public to join a Georgia Tech IBC meeting are considered upon request. No such requests were received for this meeting.

1. **A quorum being present, the meeting was called to order at 10:00 am.**

2. **Approval of September 4, 2025, Minutes**
The September IBC minutes were sent to committee review. No modifications were requested.
Motion: Approve the minutes as written.
Approve: Seven **Disapprove: none** **Abstain: none**

3. **Registrations/Amendments for Discussion at Today's Meeting**

PAABY-R100088-06/10/2025 (renewal)
Title: Study of genetic background effects in development
Funding: NSF, Discretionary
Category: Non-Exempt, BSL-2, Section III-D-4
Discussion Leaders: M-ORIA, D-NAM

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to study genetic variants in C. elegans and how changes in them are related to development. The proposed use of multicellular organisms and marker proteins indicates that this work should be classified as non-exempt, BSL-2 per NIH Guidelines Section III-D-4. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described on this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee discussed the protocol and had no concerns.

Motion: Approve the renewal protocol.
Approve: seven **Disapprove: none** **Abstain: none**

TEMENOFF-R100062-10/19/2025 (renewal)
Title: Studies in drug delivery and cell differentiation
Funding: Marcus Fnd, NSF, Emory, University of Oregon
Category: Non-Exempt, BSL-2, ABSL-2, Sections III-D-1a, III-D-3, III D-4b, III-E-1
Discussion Leaders: S-BME, T-ORIA

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to genetically modify cells to allow for cell tracking, cancer cell modification and instill immune effector cell functions. The proposed use of genomic editing components and marker proteins indicates that this work should be classified as non-exempt, BSL-2, ABSL-2 per NIH Guidelines Sections III-D-1-a, III-D-3, III-D-4b and III-E-1. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described on this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee discussed the protocol and found some discrepancies with funding details, NIH citations not correlating with some material use and unclear mention of projects that may not be related to the proposed research. Also, reviewers were unclear if and how certain models and materials would be involved in the research, and some inconsistencies between details throughout the protocol.
Motion: Return the submission to the PI to address reviewer comments and then reassign the review to the discussion leaders.
Approve: seven **Disapprove: none** **Abstain: none**

ROSENZWEIG-R100092-10/24/2025 (renewal)
Title: Evolution of drug resistance in Candida glabrata
Funding: N/A
Category: Non-Exempt, BSL-2, Section III-D-1-a
Discussion Leaders: K-EHS, K-NAM

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to carry out a set of experiments to better understand the development of resistance and the associated potential fitness costs associated with Candida glabrata. The proposed use of genomic editing components and marker proteins indicates that this work should be classified as non-exempt, BSL-2 per NIH Guidelines Section III-D-1-a. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described on this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee discussed the protocol and had no concerns.
Motion: Approve the renewal protocol.
Approve: seven **Disapprove: none** **Abstain: none**

KIM-R100237-11/01/2027 (amendment that makes the protocol Non-Exempt)
Title: Bioorthogonal methods for unveiling chemical reactivity
Funding: NIH, Discretionary
Category: Non-Exempt, BSL-2, Sections III-F-8, III-E-1
Discussion Leaders: K-BIOL, S-BME

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to regulate the activity of proteins using small molecules, understand how proteins interact with small molecules/peptides/proteins, and discover proteins that interact with bioactive small molecules. The proposed addition of B line of E. coli used for protein expression indicates that this work should now be classified as non-exempt, BSL-2, per NIH Guidelines Sections III-F-8 and III

E-1. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described on this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee discussed the protocol and found that it was unclear how the added materials would be used and for what purpose. The Committee also noted a discrepancy in containment levels. Further, the risk assessment was outdated.

Motion: Return the submission to the PI to address reviewer comments and then reassign the review to the discussion leaders.

Approve: seven **Disapprove: none** **Abstain: none**

ZHU-R100028 (renewal)
Title: T cell mechanobiology as related to viral infection and cancer
Funding: NIH, Discretionary
Category: Non-exempt, BSL-2, ABSL-1, Sections III-D-1-a, III-D-3-a, III-F-6
Discussion Leaders: K-BIOL, D-NAM

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to investigate whether a suppressive pathway involving a specific molecule, and a group of immune cells are responsible for weakening anti-tumor responses in an in vivo model. The proposed use of marker proteins and synthetic receptors indicates that this work should be classified as non-exempt, BSL-2, ABSL-1 per NIH Guidelines Sections III-D-1-a, III-D-3-a, and III-F-6. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described on this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee discussed the protocol and had no concerns.

Motion: Approve the renewal protocol.

Approve: seven **Disapprove: none** **Abstain: none**

4. **Items not requiring committee discussion or review**

The Committee has been provided with a list of protocols, amendments, and renewals to IBC registrations which were approved at or since the last Biosafety Committee meeting (including items exempt from the *NIH Guidelines*). The Committee was also provided with a list of registrations which were withdrawn, expired, or closed since the last Biosafety Committee meeting.

5. **Other business**

- Committee training on "Determining Applicability of NIH Guidelines and Containment Levels for Potential Recombinant and Synthetic Nucleic Acid Use"

Next meeting November 6, 2025